Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.…
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
Acrivon Therapeutics (NASDAQ: ACRV) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 74 employees.
The shares were at 1.150 USD on 20 November 2026, down 40.7% over 52 weeks. Its 52-week range is 0.9709 USD to 3.560 USD: the price is 67.7% below the high and 18.4% above the low.
Its market capitalisation is 49.35M USD.
Acrivon Therapeutics reports return on equity of -69.2% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 75.95M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.